

# **Anthrax Vaccine Work Group**

**David S. Stephens, MD, FIDSA  
ACIP Anthrax Vaccine Work Group**

**Advisory Committee for  
Immunization Practices  
October 26, 2017**

# **ACIP Anthrax Work Group Members**

**ACIP Members: David Stephens, Chair; Robert L. Atmar**

**Ex Officio Members: Judy Hewitt (NIH); Eric Espeland (BARDA); Alexandra Worobec (FDA); Eric Deussing (DOD); Kim Taylor (NIH); Chia-Wei Tsai (BARDA); Julianne Clifford (FDA)**

**Liaison Representatives: Richard Beigi (ACOG); Kathleen Neuzil (IDSA) ; James Campbell (AAP); Matthew Zahn (NACCHO)**

**Invited Consultants: Wendy Keitel; Arthur Friedlander; Phillip Pittman; Andy Pavia**

**CDC: William Bower, Lead**

# Terms of Reference

**Review new data on Anthrax Vaccine Adsorbed (AVA) including:**

- ❑ **New safety studies**
- ❑ **Immunogenicity, reactogenicity and logistical considerations for administering AVA via the subcutaneous versus the intramuscular route for administration as Post Exposure Prophylaxis (PEP)**
- ❑ **AVA plus CPG 7909 adjuvant data use as post-exposure prophylaxis**
- ❑ **Efficacy and immunogenicity data on dose-sparing strategies for PEP during a mass casualty incident when AVA is a limited resource**
- ❑ **Data on reduced booster schedule for pre-exposure prophylaxis**
- ❑ **Advise on the use of AVA and antitoxin for PEP when no effective antimicrobials are available or have an absolute contraindication**

# Today's session

- ❑ Discuss preparedness/operational concerns during an anthrax mass casualty event
- ❑ Review new safety data
  - Adverse events related to IM vs. SC route of administration
- ❑ Review data on immunogenicity for IM versus SC route of administration
- ❑ Summary